Philip A Philip

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5512658/publications.pdf

Version: 2024-02-01

67	3,243	186265	155660
papers	citations	28 h-index	55 g-index

70	70	70	5466
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Association of Homologous Recombinationâ€“DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers. Molecular Cancer Therapeutics, 2022, 21, 227-236.	4.1	4
2	Classification of early-stage colon cancer with ImmunoscoreÂ®: clinical evidence and case studies. Future Oncology, 2022, 18, 613-623.	2.4	2
3	Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Clinical Cancer Research, 2022, 28, 2704-2714.	7.0	57
4	Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12Câ€“Mutant Cancers. Cancer Research Communications, 2022, 2, 342-352.	1.7	12
5	Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets. Oncogene, 2022, 41, 3455-3460.	5.9	19
6	Differences in Baseline Characteristics and White Blood Cell Ratios Between Racial Groups in Patients with Pancreatic Adenocarcinoma. Journal of Gastrointestinal Cancer, 2021, 52, 160-168.	1.3	3
7	Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma. JAMA Oncology, 2021, 7, 421.	7.1	159
8	Gastrointestinal stromal tumor: a review of current and emerging therapies. Cancer and Metastasis Reviews, 2021, 40, 625-641.	5.9	39
9	Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of KRAS. Cells, 2021, 10, 1275.	4.1	4
10	Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. Oncogene, 2021, 40, 4894-4905.	5.9	19
11	Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside. Cancers, 2021, 13, 2777.	3.7	18
12	PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus. Molecular Cancer Therapeutics, 2021, 20, 1836-1845.	4.1	14
13	Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs. Cancers, 2021, 13, 4161.	3.7	14
14	Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer and Metastasis Reviews, 2021, 40, 819-835.	5.9	41
15	Molecular characterization of squamous cell carcinoma of the anal canal. Journal of Gastrointestinal Oncology, 2021, 12, 2423-2437.	1.4	7
16	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. Npj Precision Oncology, 2021, 5, 95.	5.4	9
17	Pancreatic cancer: why we must be optimistic?. Cancer and Metastasis Reviews, 2021, 40, 659-660.	5.9	0
18	Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2020, 26, 1338-1348.	7.0	28

#	Article	IF	Citations
19	The impact of ARID1A mutation on molecular characteristics in colorectal cancer. European Journal of Cancer, 2020, 140, 119-129.	2.8	37
20	Molecular Characterization of Appendiceal Goblet Cell Carcinoid. Molecular Cancer Therapeutics, 2020, 19, 2634-2640.	4.1	14
21	Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. ESMO Open, 2020, 5, e000942.	4.5	26
22	Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth. Cancers, 2020, 12, 750.	3.7	27
23	Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma. Journal of Surgical Oncology, 2020, 121, 1320-1328.	1.7	16
24	Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open, 2020, 5, e000682.	4.5	64
25	Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR) Tj ETQq1 1 0.784314 rgBT /O	4.6	34
26	Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. The Lancet Gastroenterology and Hepatology, 2020, 5, 285-294.	8.1	152
27	Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. Oncologist, 2019, 24, 319-326.	3.7	29
28	DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma. Cancers, 2019, 11, 1101.	3.7	9
29	A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas. Future Oncology, 2019, 15, 3189-3196.	2.4	64
30	A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 307 T Pancreatic Cancer. Journal of Pancreatic Cancer, 2019, 5, 35-42.	0.9	10
31	Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer. International Journal of Molecular Sciences, 2019, 20, 4826.	4.1	29
32	Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. Clinical Cancer Research, 2019, 25, 3096-3103.	7.0	65
33	Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. Cancer Treatment Reviews, 2019, 77, 1-10.	7.7	48
34	Ras and exosome signaling. Seminars in Cancer Biology, 2019, 54, 131-137.	9.6	44
35	Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma With the Introduction of New Chemotherapeutic Drugs. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 243-246.	1.3	4
36	PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors. Cancers, 2019, 11, 1902.	3.7	22

#	Article	IF	Citations
37	miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma. American Journal of Pathology, 2019, 189, 58-70.	3.8	46
38	Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges. Expert Opinion on Pharmacotherapy, 2019, 20, 535-546.	1.8	22
39	Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation. Small GTPases, 2019, 10, 367-377.	1.6	26
40	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. Molecular Cancer Research, 2018, 16, 805-812.	3.4	169
41	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncology, The, 2018, 19, e151-e160.	10.7	51
42	The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Review of Anticancer Therapy, 2018, 18, 131-148.	2.4	36
43	Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. Oncologist, 2018, 23, 1319-1327.	3.7	131
44	Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics, 2017, 16, 76-87.	4.1	69
45	Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. Oncotarget, 2017, 8, 82144-82155.	1.8	43
46	Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget, 2017, 8, 86356-86368.	1.8	147
47	Targeting macrophages to treat pancreatic cancer. Lancet Oncology, The, 2016, 17, 552-553.	10.7	7
48	Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 2784-2796.	1.6	267
49	F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities. Seminars in Cancer Biology, 2016, 36, 95-104.	9.6	29
50	The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer. Advances in Experimental Medicine and Biology, 2016, 890, 57-74.	1.6	91
51	Patterns and predictors of failure following tri-modality therapy for locally advanced esophageal cancer. Acta OncolÃ³gica, 2016, 55, 303-308.	1.8	13
52	Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition. Scientific Reports, 2015, 5, 16077.	3.3	28
53	PET Scans as a Predictive Marker of Survival in Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2015, 14, 35-40.	2.3	12
54	Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery Improves Outcome in Patients With Primary Appendiceal Mucinous Adenocarcinoma: A Pooled Analysis From Three Tertiary Care Centers. Oncologist, 2015, 20, 907-914.	3.7	25

#	Article	IF	Citations
55	Contribution of microRNAs in understanding the pancreatic tumor microenvironment involving cancer associated stellate and fibroblast cells. American Journal of Cancer Research, 2015, 5, 1251-64.	1.4	42
56	Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. Radiotherapy and Oncology, 2014, 113, 35-40.	0.6	13
57	Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single-Arm Phase II Trials. Clinical Cancer Research, 2014, 20, 4176-4185.	7.0	12
58	Dual blockade of epidermal growth factor receptor and insulinâ€like growth factor receptorâ€“1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727). Cancer, 2014, 120, 2980-2985.	4.1	78
59	Deregulation of miR-146a expression in a mouse model of pancreatic cancer affecting EGFR signaling. Cancer Letters, 2014, 351, 134-142.	7.2	41
60	Reply to A. Aref et al and E. Ben-Josef et al. Journal of Clinical Oncology, 2012, 30, 1566-1567.	1.6	0
61	Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Groupâ€“Directed Intergroup Trial S0205. Journal of Clinical Oncology, 2010, 28, 3605-3610.	1.6	570
62	Novel Targets for Pancreatic Cancer Therapy. Surgical Oncology Clinics of North America, 2010, 19, 419-429.	1.5	10
63	Abstract 5703: Up-regulation of miR-146a contributes to the inhibition of invasion of pancreatic cancer cells. Cancer Research, 2010, 70, 5703-5703.	0.9	22
64	First- and second-line treatment of metastatic pancreatic adenocarcinoma: the conundrum continues. Gastrointestinal Cancer Research: GCR, 2009, 3, 37-9.	0.7	2
65	Targeted therapies for pancreatic cancer. Gastrointestinal Cancer Research: GCR, 2008, 2, S16-9.	0.7	15
66	Phase II study of CI-958 in colorectal cancer. Cancer Chemotherapy and Pharmacology, 1999, 43, 162-164.	2.3	4
67	Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma. Cancer Chemotherapy and Pharmacology, 1997, 40, 225-227.	2.3	17